Devon Price
Family · Keller, TXNPI 1336731124
Payments from drug & device makers
Across 252 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$570
- Novo Nordisk$523
- AstraZeneca$430
- Lilly USA, LLC$361
- Pfizer$311
- Boehringer Ingelheim$301
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,668100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $570 |
| Novo Nordisk | 31 | $523 |
| AstraZeneca | 15 | $430 |
| Lilly USA, LLC | 24 | $361 |
| Pfizer | 18 | $311 |
| Boehringer Ingelheim | 17 | $301 |
| GSK | 12 | $272 |
| Bayer | 10 | $178 |
| Amgen(2 entities) | 10 | $173 |
| Abbott | 9 | $162 |
| Exact Sciences | 7 | $124 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $117 |
| Nevro Corp. | 6 | $116 |
| Dexcom, Inc. | 5 | $113 |
| Daiichi Sankyo Inc. | 5 | $108 |
| Astellas Pharma US Inc | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Medtronic | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 1 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Kaleo, Inc. | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| Bausch Health US, LLC | 2 | $35 |
| Inspire Medical Systems, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Genentech USA, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$4,668 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $69,608 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $24,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $24,271 |
| JardianceEmpagliflozin | 23 | $20,565 |
| EliquisApixaban | 13 | $17,734 |
| FarxigaDapagliflozin Propanediol | 20 | $15,369 |
| MounjaroTirzepatide | 11 | $10,524 |
| Azelastine Hcl | 93 | $3,546 |
| Atorvastatin Calcium | 157 | $1,203 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $832 |
| Levothyroxine Sodium | 110 | $821 |
| Gabapentin | 42 | $704 |
| SynthroidLevothyroxine Sodium | 11 | $598 |
| Bupropion XlBupropion Hcl | 21 | $540 |
| Metformin Hcl | 59 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $523 | $69,60841 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $430 | $39,64046 claims |
| GSKTrelegy Ellipta | $272 | $24,60922 claims |
| Boehringer IngelheimJardiance | $301 | $20,56523 claims |
| PfizerEliquis | $311 | $17,73413 claims |
| Lilly USA, LLCMounjaro | $361 | $10,52411 claims |
| AbbVieSynthroid | $570 | $59811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Keller
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.